Clinical Trials Logo

Leiomyoma clinical trials

View clinical trials related to Leiomyoma.

Filter by:

NCT ID: NCT06325501 Recruiting - Myoma;Uterus Clinical Trials

Misoprostol Versus Oxytocin Infusion On Reducing Blood Loss During Abdominal Myomectomy

Start date: March 1, 2024
Phase: Phase 3
Study type: Interventional

Uterine leiomyomas, or fibroids, are common benign tumors among women, especially those over 35 years old. They can cause various issues, including heavy menstrual bleeding, anemia, pelvic pain, and pressure symptoms. Surgery is often necessary for symptomatic fibroids, with hysterectomy recommended for women over 40 and myomectomy for those wishing to preserve their uterus. Myomectomy can be performed using different surgical approaches but can be associated with significant morbidity, particularly major blood loss, especially in abdominal myomectomy, where up to 20% of women may require blood transfusion. Various interventions have been introduced to reduce bleeding during myomectomy, such as tourniquets, bupivacaine plus epinephrine infiltration, vasopressin injection, preoperative GnRH agonist administration, and preoperative ascorbic acid injection. However, these strategies may have complications, be ineffective, expensive, or require extra steps. Oxytocin, primarily secreted from the pituitary gland, is crucial for uterine contraction during labor and delivery, and is used to prevent postpartum uterine atony and bleeding. However, caution is needed in its use, especially in women with heart disease or hypovolemia. Misoprostol, a prostaglandin E1 analogue, can reduce bleeding during myomectomy by promoting myometrial contractions and reducing uterine artery blood flow. It can be administered via multiple routes, with rectal administration showing advantages in maintaining high plasma concentrations during surgery. Studies have investigated the effectiveness of single preoperative rectal doses of misoprostol versus preoperative oxytocin in reducing bleeding during abdominal myomectomy.

NCT ID: NCT06269809 Recruiting - Fibroid Uterus Clinical Trials

Temporary Artery Clipping for Robotically-assisted Myomectomy, a Multicentric Randomized Controlled Trial

TACROM
Start date: May 4, 2023
Phase: N/A
Study type: Interventional

This study aims to investigate the efficacy of temporary clipping of the uterine artery and utero-ovarian ligament during robotically assisted myomectomy (RAM) for uterine fibroids. While RAM is increasingly used for myomectomy, bleeding control remains challenging. Temporary clipping of arteries has shown promise in conventional laparoscopy but has not been studied in RAM. This randomized controlled trial will assess primary endpoints such as estimated blood loss, need for transfusion, and hemoglobin drop, alongside secondary outcomes like complication rates and operation time.

NCT ID: NCT06244251 Active, not recruiting - Uterine Fibroid Clinical Trials

Comparison Between Laparoendoscopic Single-site Surgery and Multi-port Laparoscopy in Treating Uterine Fibroids

Start date: June 24, 2023
Phase: N/A
Study type: Interventional

Myomectomy was preferably applied in females with reproductive requirements, which could be achieved by transumbilical laparoendoscopic single-site surgery (TU-LESS) or multi-port laparoscopic surgery (MPLS). Power morcellation used in MPLS was correlated with unidentified risk of tumor dissemination, especially in cases with accidental surgical findings of uterine sarcoma or leiomyosarcoma. Moreover, TU-LESS was reported to exceed MPLS in fast recovery. Therefore, the aim of this prospective cohort study is to compare the effectiveness of fast recovery and relative risk of tumor dissemination between TU-LESS and MPLS in myomectomy for the treatment of uterine fibroids.

NCT ID: NCT06234670 Not yet recruiting - Recurrence Clinical Trials

Risk Factors and A Prediction Model of Recurrence of Uterine Fibroids

Start date: January 25, 2024
Phase:
Study type: Observational

To research risk factors for recurrence of uterine fibroids and build a prediction model of recurrence of uterine fibroids to facilitate the early detection as well as the early intervention for patients who are prone to recur.

NCT ID: NCT06208891 Recruiting - Clinical trials for Women With Uterine Myoma

Clinical Outcomes of Robotic Myomectomy

Start date: November 21, 2023
Phase:
Study type: Observational

To identify the predictors of perioperative outcomes in women who receive robotic myomectomy

NCT ID: NCT06153667 Not yet recruiting - Uterine Fibroid Clinical Trials

Bearing nsPVA Embolization for Uterine Artery Embolization

Start date: April 2024
Phase:
Study type: Observational

This is a prospective, multicenter, observational, post-market clinical follow-up study in subjects treated with Bearing nsPVA Embolization Particles for uterine fibroid embolization. Data collection will include safety and performance outcome relating to the use of Bearing nsPVA, through 6 months.

NCT ID: NCT06143631 Not yet recruiting - Leiomyoma Clinical Trials

Prescription of Letrozole for Uterine Myoma

PLUM
Start date: March 1, 2024
Phase: Phase 4
Study type: Interventional

The PLUM Study is a randomized, double-blinded, 2-arm, parallel-group, placebo-controlled trial is designed to compare the efficacy of letrozole versus placebo on leiomyoma-related symptoms and quality of life as well as leiomyoma and uterine size.

NCT ID: NCT06135870 Recruiting - Leiomyoma Clinical Trials

Role of Senescent Cells in Uterine Fibroid Pathogenesis (SOUL Study)

SOUL
Start date: November 1, 2023
Phase:
Study type: Observational

The investigators are evaluating the role of senescent cells in uterine fibroids.

NCT ID: NCT06115408 Recruiting - Uterine Leiomyoma Clinical Trials

Evaluation of Using Dienogest and N-Acetyl Cysteine on the Volume of Uterine Leiomyoma

Start date: July 1, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

This 2 arm randomized clinical trial will assess the impact of Dienogest and N-Acetyl Cysteine on volume reduction of uterine leiomyoma

NCT ID: NCT06114758 Active, not recruiting - Clinical trials for Postoperative Complications

Comparison Effectiveness of Rectal Misoprostol & Intravenous Tranexamic Acid Reducing Hemorrhage in Myomectomy

Start date: September 1, 2023
Phase:
Study type: Observational [Patient Registry]

Fibroids are the most commonly encountered tumors in the female reproductive system. In patients, fibroids most often lead to abnormal uterine bleeding and the resulting anemia. In some cases, they can cause infertility or habitual abortions. Another complaint caused by fibroids is pain due to pressure and effects on adjacent organs. Very large fibroids can lead to abdominal swelling. Therefore, if a patient becomes symptomatic due to fibroids, myomectomy or, if necessary, hysterectomy is required. Because fibroids have a significant blood supply, there is a high risk of intraoperative bleeding and related complications. Additionally, the most common complication in these patients after the operation is bleeding. In many of these patients, intraoperative or postoperative blood transfusions are performed. If bleeding cannot be intervened early in these patients, hemodynamic instability, shock, coagulopathy, and, in the final stage, death can occur due to hemorrhage. Therefore, both intraoperative and postoperative bleeding control is of vital importance in patients undergoing myomectomy.